BioXcel Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• BioXcel Therapeutics, Inc. showed a decrease of -4.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,103.5%.
• Historical annual values: Fiscal year 2025: $28.42 million | Fiscal year 2024: $29.85 million | Fiscal year 2023: $65.22 million | Fiscal year 2022: $193.73 million | Fiscal year 2021: $232.97 million | Fiscal year 2020: $213.12 million | Fiscal year 2019: $32.43 million | Fiscal year 2018: $42.57 million | Fiscal year 2017: $887.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026